Aptevo Therapeutics Inc (NASDAQ:APVO) Director Daniel Abdun-Nabi purchased 16,667 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was bought at an average cost of $0.90 per share, with a total value of $15,000.30. Following the completion of the acquisition, the director now directly owns 109,351 shares of the company’s stock, valued at $98,415.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
APVO traded up $0.01 on Thursday, reaching $0.87. The stock had a trading volume of 155,700 shares, compared to its average volume of 537,294. The company has a market cap of $39.68 million, a P/E ratio of -0.36 and a beta of 2.39. The company has a 50-day moving average price of $0.85. The company has a current ratio of 3.15, a quick ratio of 2.91 and a debt-to-equity ratio of 0.60. Aptevo Therapeutics Inc has a 12-month low of $0.67 and a 12-month high of $5.80.
Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, hitting analysts’ consensus estimates of ($0.44). The business had revenue of $7.02 million during the quarter, compared to analysts’ expectations of $6.30 million. Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. Analysts predict that Aptevo Therapeutics Inc will post -1.4 EPS for the current year.
APVO has been the topic of a number of research analyst reports. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Roth Capital reissued a “buy” rating on shares of Resverlogix in a research report on Thursday, May 23rd. Finally, Piper Jaffray Companies raised their target price on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Aptevo Therapeutics has a consensus rating of “Hold” and an average target price of $7.88.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Further Reading: How does the Beige Book influence monetary policy?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.